<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180116038387N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-02-26</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Effectiveness of Oral Immunotherapy in patients with allergy to egg white</public_title>
      <acronym></acronym>
      <scientific_title>The effectiveness of oral immunotherapy with egg white for desensitizing the patients with IgE mediated sensitization to egg white and comparison with the control group</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-02-04</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>14</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/28989</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: The samples were randomly selected(according to random number table)  from patients referred to the Asthma and Allergy Clinic of Rasool Akram Hospital and Allergy Clinic of Jahad , Blinding description: After obtaining informed consent from all the patients to participate in the study, they will not inform about dividing them in groups(Immunotherapy or placebo).</study_design>
      <phase>N/A</phase>
      <hc_freetext>Condition 1: IgE-mediated sensitization to Egg white. Condition 2: IgE-mediated sensitization to Egg white.</hc_freetext>
      <i_freetext>Intervention group:  Three phase including an initial dose escalation during 5 days of hospitalization, to continue the use of received dose at home, to increase the dose up to achieve maintenance dose and maintain   dose after 6 months according to the protocol of use of pasteurized raw egg white( produced by Telavang Co.). To escalate the dose in build-up phase, the patients will be hospitalized for 5 days in Rasool Akram Hospital. Obviously, during the hospitalization and the build-up phase, all treatment will be available to manage the possible attack of an anaphylactic reaction. For the safety of the patients, premedication will be done with the antihistamine (H1 and H2) and ALRA. In case of a mild reaction, antihistamines will be administered, and in case of intermediate and severe reactions,  intramuscular epinephrine and Prednisolone and Salbutamol will be added.The interval between escalating doses is 4 hours. In case of a mild, moderate and severe reactions will be returned to one and two previous phases. Also, to control the possible anaphylactic attack in the maintenance phase, necessary training will be given to the patient or their parents..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is A few studies have been done in the field of oral Immunotherapy in Iran and we would like to continue this process in the future projects. So, the time of publishing the data file has been not defined.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Dr. Vahid Ghobadi Dana</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrat Rasoul Akram Hospital, Niayesh Street, Sattarkhan Street, Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6651 4001</telephone>
        <email>drghobadidana@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Vahid Ghobadi Dana</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrat Rasoul Akram Hospital, Niayesh Street, Sattarkhan Street,Tehran</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1445613131</zip>
        <telephone>+98 21 6655 9595</telephone>
        <email>drghobadidana@yahoo.com</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patients referring to Department of Asthma and Allergy in Rasool Akram Hospital and Jahad Clinic with a history of allergic reaction to egg white up to 2 hours after ingestion and positive Skin Prick test to Egg white
The inability to pass the Oral Food Challenge (OFC) according to the protocol of Middelton Book with using pasteurized raw egg white (Produced by Telavang Egg Industries Co.)</inclusion_criteria>
      <agemin>4 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Age less than 4 years old
History of Cardiovascular diseases
Use of Beta-Blockers and ACE
Severe and Uncontrolled Asthma</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>T78.0</hc_code>
      <hc_code>T78.1</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Anaphylactic reaction due to food</hc_keyword>
      <hc_keyword>Other adverse food reactions, not elsewhere classified</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group:  Three phase including an initial dose escalation during 5 days of hospitalization, to continue the use of received dose at home, to increase the dose up to achieve maintenance dose and maintain   dose after 6 months according to the protocol of use of pasteurized raw egg white( produced by Telavang Co.). To escalate the dose in build-up phase, the patients will be hospitalized for 5 days in Rasool Akram Hospital. Obviously, during the hospitalization and the build-up phase, all treatment will be available to manage the possible attack of an anaphylactic reaction. For the safety of the patients, premedication will be done with the antihistamine (H1 and H2) and ALRA. In case of a mild reaction, antihistamines will be administered, and in case of intermediate and severe reactions,  intramuscular epinephrine and Prednisolone and Salbutamol will be added.The interval between escalating doses is 4 hours. In case of a mild, moderate and severe reactions will be returned to one and two previous phases. Also, to control the possible anaphylactic attack in the maintenance phase, necessary training will be given to the patient or their parents.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Desensitization. Timepoint: 6 months. Method of measurement: Pass the Oral food challenge test after 6 months use of egg white.</prim_outcome>
      <prim_outcome>Specific IgE concentration to Egg white. Timepoint: 6 months. Method of measurement: Immunocap.</prim_outcome>
      <prim_outcome>Specific IgG4 concentration to Egg white. Timepoint: 6 months. Method of measurement: ImmunoCAP.</prim_outcome>
      <prim_outcome>The size of Skin Prick Test. Timepoint: 6 months. Method of measurement: The size of  wheal and Flare(mm).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Telavang Company</sponsor_name>
      <sponsor_name>Dr. Vahid Ghobadi Dana</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
      <source_name>Telavang Company</source_name>
      <source_name>Dr. Vahid Ghobadi Dana</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-01-15</approval_date>
        <contact_name>Ethics committee of Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical Sciences, Hemmat Highway, Tehran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
